Reexamining Misconceptions About β-Blockers in Patients With Diabetes

IN BRIEF Because effectively managing patients with diabetes and hypertension requires multiple medications, the appropriate selection of a treatment regimen with good tolerability and simplified dosing is crucial. Despite the proven benefits of β-blockers in lowering blood pressure and improving cardiovascular morbidity, many physicians are reluctant to prescribe them to patients with diabetes and hypertension. This reluctance is based on the misconception that β-blockers worsen glycemic control, insulin sensitivity, and dyslipidemia and mask hypoglycemia. Unlike traditional β-blockers, vasodilatory β-blockers have favorable tolerability and metabolic profiles while offering effective blood pressure control.